Lilly shares falter after quarterly earnings report

Back to TopCommentsE-mailPrintBookmark and Share

Eli Lilly and Co.’s first-quarter profit beat the expectations of Wall Street analysts, but its stock price slipped anyway Monday morning, along with the broader market.

The Indianapolis-based drugmaker, which announced its quarterly results Monday morning, recorded restructuring charges due to its downsizing as it tries to develop new drugs to help it shrug off its looming patent expirations.

Lilly earned $1.1 billion, or 95 cents per share, during the three months ended March 31. Those results were at least 15 percent lower than during the same quarter a year ago.

However, excluding charges related to the company’s downsizing and higher research costs from drug development partnerships, Lilly would have earned $1.24 per share.

Analysts surveyed by Thomson Reuters, who typically exclude special charges from their forecasts, were expecting $1.16 per share.

The surprise seemed to matter little to investors, as Lilly’s stock fell as much as 1.8 percent in morning trading,  to $35.37 per share. The Dow Jones industrial average fell as much as 2 percent Monday morning after a bond rating agency cut its outlook on U.S. government debt.

Also, analysts focused on Lilly’s longer-term challenges: its best-selling drug, Zyprexa, will lose patent protection in October, costing Lilly most of its $5 billion in annual sales to cheaper generic copies.

"Granted, it's always good when quarterly earnings are better than expected, but the question on investors' minds is how Lilly will fare post-Zyprexa," Miller Tabak analyst Les Funtleyder told the Reuters news agency.

Because one of Lilly’s blockbusters, the cancer drug Gemzar, already lost patent protection late last year, and because two other big products, Cymbalta and Evista, will face generic competitors in the next three years, the company stands to lose roughly $10 billion in sales.

Lilly officials have tried to focus investors on the areas of the company that are and will continue to grow. Its volume of sales in Japan rose 34 percent in the quarter. Its volume of China sales rose 23 percent. And its animal health business grew 25 percent.

And Lilly officials emphasized that they now have 69 experimental drugs in human testing, including nine in Phase 3, the final stage before submitting for market approval.

“So far, 2011 is playing out as anticipated,” said Derica Rice, Lilly’s chief financial officer. He added, “This pipeline serves as the foundation of our growth [after 2014].”

First-quarter sales at Lilly rose 6 percent, to $5.8 billion, mainly on the strength of international sales. Analysts were expecting revenue of $5.7 billion.

Lilly lowered its full-year profit forecast about 6 cents per share—to reflect its restructuring charges. It now expects to earn $3.86 to $4.01 per share.

Lilly spent $76.3 million on severance as it continued its efforts to trim 5,500 workers by year’s end. The company said it is 75 percent of the way toward that goal.

Lilly also spent another $26 million on its restructuring efforts. And two research partnerships—with Germany-based Boehringer Ingelheim and with Australia-based Acrux Ltd.—cost the company $438 million in the quarter.


Post a comment to this story

We reserve the right to remove any post that we feel is obscene, profane, vulgar, racist, sexually explicit, abusive, or hateful.
You are legally responsible for what you post and your anonymity is not guaranteed.
Posts that insult, defame, threaten, harass or abuse other readers or people mentioned in IBJ editorial content are also subject to removal. Please respect the privacy of individuals and refrain from posting personal information.
No solicitations, spamming or advertisements are allowed. Readers may post links to other informational websites that are relevant to the topic at hand, but please do not link to objectionable material.
We may remove messages that are unrelated to the topic, encourage illegal activity, use all capital letters or are unreadable.

Messages that are flagged by readers as objectionable will be reviewed and may or may not be removed. Please do not flag a post simply because you disagree with it.

Sponsored by

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
Subscribe to IBJ
  1. Kent's done a good job of putting together some good guests, intelligence and irreverence without the inane chatter of the other two shows. JMV is unlistenable, mostly because he doesn't do his homework and depends on non-sports stuff to keep HIM interested. Query and Shultz is a bit better, but lack of prep in their show certainly is evident. Sterling obviously workes harder than the other shows. We shall see if there is any way for a third signal with very little successful recent history to make it. I always say you have to give a show two years to grow into what it will become...

  2. Lafayette Square, Washington Square should be turned into office parks with office buildings, conversion, no access to the public at all. They should not be shopping malls and should be under tight security and used for professional offices instead of havens for crime. Their only useage is to do this or tear them down and replace them with high rise office parks with secured parking lots so that the crime in the areas is not allowed in. These are prime properties, but must be reused for other uses, professional office conversions with no loitering and no shopping makes sense, otherwise they have become hangouts long ago for gangs, groups of people who have no intent of spending money, and are only there for trouble and possibly crime, shoplifting, etc. I worked summers at SuperX Drugs in Lafayette Square in the 1970s and even then the shrinkage from shoplifting was 10-15 percent. No sense having shopping malls in these areas, they earn no revenue, attract crime, and are a blight on the city. All malls that are not of use should be repurposed or torn down by the city, condemned. One possibility would be to repourpose them as inside college campuses or as community centers, but then again, if the community is high crime, why bother.

  3. Straight No Chaser

  4. Seems the biggest use of TIF is for pet projects that improve Quality Of Life, allegedly, but they ignore other QOL issues that are of a more important and urgent nature. Keep it transparent and try not to get in ready, fire, Aim! mode. You do realize that business the Mayor said might be interested is probably going to want TIF too?

  5. Gary, I'm in complete agreement. The private entity should be required to pay IPL, and, if City parking meters are involved, the parking meter company. I was just pointing out how the poorly-structured parking meter deal affected the car share deal.